Guerbet is a leading provider of Sodium Chloride in prefilled syringes used for power injectors.
-
Ultraject® prefilled sodium chloride syringes, used in the OptiVantage®, OptiStar® Elite and Illumena® Neo Injectors, provide convenience and efficiency in flushing compatible contrast imaging agents.
Clinical Usage
- Ensures proper needle placement and reduces risk of CM extravasation during Patency Testing2
- Provides a tighter bolus of contrast, creating prolonged and increased enhancement during CTA and MRA scans3
Ordering Information
| Description | Qty | Unit | Size | Order # | 11 Digit NDC |
| Sodium Chloride 0.9%, Ultraject® prefilled syringe | 20 | each | 125 mL | 118881 | 00019118881 |
| Sodium Chloride 0.9%, Ultraject® prefilled syringe, RFID Enabled | 20 | each | 125 mL | 118827 | 00019118827 |
Disclaimers
L-F Injectors are Class II Medical Devices in the United States. For complete information about precautions and optimal usage conditions for these medical devices, consult the full instructions for use supplied with each device or with your local Guerbet representative(s).
Caution: US Federal Law restricts this device to sale by or on the order of a physician.
Ultraject® Prefilled Syringes are a registered trademark of Guerbet LLC, and is available by prescription only.
References
1 Sodium Chloride Injection USP 0.9% Prescribing Information. Princeton, NJ: Guerbet LLC; Dec 2018.
2 ACR Manual on Contrast Media, version 10.2. American College of Radiology, Reston, VA, 2020, 17.
3 Bae, K. T. Intravenous contrast, medium administration and scan timing at CT: considerations and approaches Radiology. 2010 Jul; 256 (1): 48.
GU05201138
Important Safety Information
Indications and Usage
125 mL Syringe: Sodium Chloride Injection USP 0.9% is indicated for use in flushing compatible contrast agents through Liebel-Flarsheim intravenous administration sets into indwelling intravascular access devices only when delivered by the following Liebel-Flarsheim power injectors: Angiomat® Illumena®, Illumena® Neo, CT9000®, CT9000® ADV, Optistat®, Optivantage® and Optistar® Elite.
Contraindications
None.
Warnings and Precautions
- Air Embolism: Remove all air from the syringe and associated tubing prior to injection to avoid air embolus with the associated risk of stroke, organ ischemia and/or infarction, and death.
- Infectious Complications: Use of damaged syringe or failure to maintain aseptic technique may result in infection, sepsis and death.
- Fluid Overload: Sodium Chloride Injection USP 0.9% may cause fluid overload in patients with congestive heart failure, severe renal insufficiency, and in clinical states with edema, sodium retention, or hypematremia. Consider each patient's age, body weight, fluid status, concomitant medical conditions and planned radiological procedure to determine if use of Sodium Chloride Injection, USP 0.9% is appropriate.
- Extravasation: Extravasation of the Sodium Chloride Injection USP 0.9% may cause mechanical compression of neurovascular structures. Extravasation of contrast agent may result in tissue injury by osmolar and direct cytotoxicity. Establish intravascular catheter patency prior to the administration of Sodium Chloride Injection USP 0.9%.
Adverse Reactions
Reported adverse reactions include:
- Air embolization with stroke, chest pain, and dyspnea
- Arrhytmia
- Hypotension
- Myocardial infarction
- Sepsis
- Febril response
- Local tenderness
- Infection at the site of injection
- Venous thrombosis or phlebitis extending from injection site
- Extravasation
- Fluid overload
- Hypervolemia
Use in Specific Populations
- Pregnancy: Risk Summary: Administration of Sodium Chloride Injection USP 0.9% is not known to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Sodium Chloride Injection USP 0.9%. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
- Lactation: Risk Summary: Appropriate administration of Sodium Chloride Injection USP 0.9% is not known to cause harm to breastfed infant.
- Pediatric Use: Safety and effectiveness of Sodium Chloride Injection USP 0.9% administered by power injection in pediatric patients have not been established. Administration of Sodium Chloride Injection USP 0.9% to pediatric patients by power injection is not recommended. When performing manual injection of Sodium Chloride Injection USP 0.9% to pediatric patients, take into account the patient's weight, fluid status, and concomitant medical conditions to determine if use of Sodium Chloride Injection USP 0.9% is appropriate. The safety manual injection of Sodium Chloride Injection USP 0.9% in pediatric patients is supported by reported clinical experience with intravenous infusion and flush of sodium chloride injection in pediatric patients. To minimize the risk of fluid overload, use the smallest dose of Sodium Chloride Injection USP 0.9% necessary for manually flushing contrast agent through the vascular access line.
- Geriatric Use: No clinical studies of Sodium Chloride Injection USP 0.9% were conducted. Other reported clinical experience with sodium chloride injection has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Overdosage
Use of Sodium Chloride Injection USP 0.9% may pose a threat of overdose marked by electrolyte disturbance and/or fluid overload, particularly in pediatric patients and patients with compromised renal or cardiac function. In the event of overdosage, discontinue the infusion, reevaluate the patient and institute appropriate corrective action.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.